Odylia Therapeutics works with some amazing patient groups. These groups continuously work on rare diseases for almost six years. These groups have a deep understanding of the disease and are often the first to see new treatments develop. Patient groups contribute significantly to the research and development landscape by identifying new treatments and supporting patients. They also advocate for the rights of patients and support them emotionally and financially.

Patient Groups Tackling Challenges Pharma Isn’t Prepared to Face

Patient groups are tackling challenges that pharma isn’t prepared to face. Patient groups are doing grassroots work on rare diseases. They are making progress, even if it’s at a slow pace. Patient groups are fighting to make a difference, even if it’s just for one patient.

Patient groups are doing grassroots work on rare diseases. They are making progress, even if it’s at a slow pace. Patient groups are fighting to make a difference, even if it’s just for one patient.

Odylia partners with Patient Groups, academic institutions, and industry to accelerate therapeutic development for rare diseases through our Brydge Solutions program. Together, we can make a difference.

Brydge Solutions is looking for new partners. If you know a patient group or rare disease company that is looking for a partner, please visit our website.

USHIC Program Update

In partnership with the Usher2020 Foundation, FAUN, Zymalab, and our collaborations in the Czech Republic, Odylia is now planning to file a gene replacement therapy in rare hereditary blindness to the US agency in the first half of 2024. This is a significant milestone for the program and for the field of gene therapy for rare diseases.

RPGRIP1 Program Update

The RPGR gene therapy program (OT-004) continues to make progress towards next steps. We have licensed the technologies directly to pharma, and more recently, salvaging their assets from crumbling BioPharma. Patient groups have created their own successful companies that are better positioned to navigate the usual setbacks, thereby ensuring promising therapeutics continue to move forward. They have the expertise, the knowledge, and the passion to make a real difference.

RPGRIP1 Gene Therapy Program Campaign

Our goal is to reach clinical trials in 2025 to tackle RPGRIP1. Thanks to amazing and generous donors we are getting closer. The RPGRIP1 gene therapy program (OT-004) continues to make progress towards next steps. We have licensed the technologies directly to pharma, and more recently, salvaging their assets from crumbling BioPharma. Patient groups have created their own successful companies that are better positioned to navigate the usual setbacks, thereby ensuring promising therapeutics continue to move forward. They have the expertise, the knowledge, and the passion to make a real difference.

e-News - Find out about new products, promotions, and events.

Follow Us on Facebook.

info@odylia.org

Visit our Website.

Follow the link HERE.